NanoSmart's multiple platform technologies can enable the
NEXT GENERATION OF BIOPHARMACEUTICALS
for treating all solid-tumor cancers, including:
breast, prostate, lung, and rare childhood cancers.
NanoSmart's patented, human-derived, anti-nuclear antibody (ANA) binds to necrotic tissue that is present in and around all solid tumors. When a tumor grows uncontrollably, parts of the tumor are cut off from the blood supply and die, leaving pockets of necrosis (massive cell death) within the tumor.
Because ANA does not target the cancer cells themselves, but rather materials released by dead cancer cells that are co-located with the tumor, ANA can be used to effectively and universally target all types of solid tumors. This versatility allows NanoSmart to focus its initial efforts on developing life-saving therapies for rare pediatric cancers that are traditionally underserved by drug developers.
ANA Targeted Nanoparticles
Lipid nanoparticles, such as liposomes and nanoemulsions, can be used to encapsulate existing and FDA-approved active pharmaceutical ingredients (APIs).
Incorporating an API into a nanoparticle inherently improves its safety and efficacy profile in two ways:
The lipid barrier serves as a protective barrier between the highly-toxic API and healthy tissues it comes into contact with while in circulation.
The composition and size of the nanoparticle can be manipulated to optimize bioavailability and tissue distribution.
NanoSmart's lipid nanoparticle formulations are additionally conjugated to its patented tumor-targeting ANA to "anchor" targeted nanoparticles at the tumor sites, and thereby achieve focused delivery of the API to the tumor site where it is needed most.
Thermally Sensitive Nanoemulsion
Lipid nanoparticles are susceptible to leakage of the encapsulated API during storage. Drug developers must strike the right balance between a shelf life that is long enough to be practical and cost-effective for storage, but short enough to enable steady and effective release the drug once it is administered to the patient. The industry has traditionally struggled to develop lipid nanoparticle drugs with these desirable stability characteristics.
NanoSmart’s nanoemulsion platform have demonstrated an enhanced stability profile that allows long-term storage without lyophilization or complicated reconstitution steps. Formulations under development can remain stable while refrigerated for several months, and then release the encapsulated API over a 24-hour period once brought to body temperature.
NanoSmart's proprietary nanoemulsion platform can also be conjugated to ANA to maximize the benefits of targeted nanoparticle drug delivery.
Licensing and Partnerships
NanoSmart Pharmaceuticals has developed several novel drug-delivery platforms with the potential to improve the safety and efficacy of a virtually unlimited number of existing cancer drugs. As NanoSmart's human-derived antibody is non-tumor marker specific (targeting areas of necrosis present in all solid tumors), we present a unique opportunity for industry to vastly improve existing products and to efficiently expand product pipelines while minimizing clinical and regulatory risk.
If you are interested in licensing, partnership or investment opportunities, please CONTACT US for additional information.